Evarist Feliu-Frasnedo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10195506/publications.pdf

Version: 2024-02-01

144 papers 3,652 citations

30 h-index 53 g-index

159 all docs

159 docs citations

159 times ranked 3712 citing authors

#	Article	IF	CITATIONS
1	Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia. Blood, 2021, 137, 1879-1894.	0.6	48
2	A pediatric regimen for adolescents and young adults with Philadelphia chromosomeâ€negative acute lymphoblastic leukemia: Results of the ALLREO8 PETHEMA trial. Cancer Medicine, 2020, 9, 2317-2329.	1.3	13
3	Plasma Epstein-Barr Virus Load as an Early Biomarker and Prognostic Factor of Human Immunodeficiency Virus–related Lymphomas. Clinical Infectious Diseases, 2019, 68, 834-843.	2.9	11
4	Diagnostic and prognostic contribution of targeted NGS in patients with tripleâ€negative myeloproliferative neoplasms. American Journal of Hematology, 2019, 94, E264-E267.	2.0	17
5	Molecular profiling refines minimal residual diseaseâ€based prognostic assessment in adults with Philadelphia chromosomeâ€negative Bâ€cell precursor acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2019, 58, 815-819.	1.5	6
6	Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group. Cancer, 2019, 125, 2810-2817.	2.0	13
7	The poor prognosis of low hypodiploidy in adults with Bâ€eell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients. British Journal of Haematology, 2019, 186, 263-268.	1.2	6
8	Increased survival due to lower toxicity for highâ€risk Tâ€cell acute lymphoblastic leukemia patients in two consecutive pediatricâ€inspired PETHEMA trials. European Journal of Haematology, 2019, 102, 79-86.	1.1	14
9	Consistency of the Moreau <scp>CLL</scp> score. Journal of Clinical Laboratory Analysis, 2018, 32, e22376.	0.9	4
10	Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55–65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia. Leukemia Research, 2018, 68, 79-84.	0.4	9
11	Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia. Leukemia and Lymphoma, 2018, 59, 146-154.	0.6	17
12	Adoption of Bio/Data Collagen for the assessment of platelet function with the Multiplate \hat{A}^{\otimes} Analyzer. Thrombosis Research, 2018, 161, 33-35.	0.8	4
13	Difference in <scp>CD</scp> 5 and <scp>CD</scp> 10 expression according to anatomic site. International Journal of Laboratory Hematology, 2018, 40, e4-e7.	0.7	2
14	DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features. Epigenetics, 2018, 13, 8-18.	1.3	14
15	Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia. Journal of Hematology and Oncology, 2018, 11, 96.	6.9	19
16	Efficacy and safety of native versus pegylated <i>Escherichia coli</i> asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia. Leukemia and Lymphoma, 2018, 59, 1634-1643.	0.6	13
17	Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine. Oncotarget, 2018, 9, 19342-19355.	0.8	15
18	Frequency and prognostic significance of $t(v;11q23)/KMT2A$ rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. Leukemia and Lymphoma, 2017, 58, 145-152.	0.6	7

#	Article	IF	CITATIONS
19	Epstein–Barr viral loads and serum free light chains levels are potential follow-up markers of HIV-related lymphomas. Leukemia and Lymphoma, 2017, 58, 211-213.	0.6	4
20	PronÃ ³ stico similar de los linfomas transformados y los linfomas difusos de células B grandes de novo en pacientes tratados con inmunoquimioterapia. Medicina ClÃnica, 2017, 148, 243-249.	0.3	1
21	Utilidad del lavado broncoalveolar y la citometrÃa de flujo en pacientes con hemopatÃas malignas e insuficiencia respiratoria. Medicina ClÃnica, 2017, 148, 297-302.	0.3	0
22	Incidence and prognostic significance of nephrotoxicity in patients receiving eshap as salvage therapy for lymphoma. Leukemia Research, 2017, 58, 98-101.	0.4	3
23	Retinal vein occlusion and paroxysmal nocturnal hemoglobinuria. Journal of Thrombosis and Thrombolysis, 2017, 44, 63-66.	1.0	2
24	HIV-infection has no prognostic impact on advanced-stage Hodgkin lymphoma. Aids, 2017, 31, 1445-1449.	1.0	14
25	Copy number profiling of adult relapsed Bâ€cell precursor acute lymphoblastic leukemia reveals potential leukemia progression mechanisms. Genes Chromosomes and Cancer, 2017, 56, 810-820.	1.5	21
26	Relapse risk after autologous stem cell transplantation in patients with lymphoma based on CD34+ cell dose. Leukemia and Lymphoma, 2017, 58, 916-922.	0.6	5
27	Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features. Oncotarget, 2016, 7, 57021-57035.	0.8	26
28	Highly variable mutational profile of <i><scp>ASXL</scp>1</i> in myelofibrosis. European Journal of Haematology, 2016, 97, 331-335.	1.1	6
29	Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group. Leukemia Research, 2016, 41, 12-20.	0.4	41
30	HIV-infection impact on clinical–biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era. Aids, 2015, 29, 811-818.	1.0	37
31	Prognostic significance of copy number alterations in adolescent and adult patients with precursor <scp>B</scp> acute lymphoblastic leukemia enrolled in <scp>PETHEMA</scp> protocols. Cancer, 2015, 121, 3809-3817.	2.0	43
32	Co-existence of <i>JAK2 </i> V617F and <i>CALR </i> half in primary myelofibrosis. Leukemia and Lymphoma, 2015, 56, 2973-2974.	0.6	21
33	The long term follow-up of early stage follicular lymphoma treated with radiotherapy, chemotherapy or combined modality treatment. Leukemia Research, 2015, 39, 853-858.	0.4	15
34	A thirty-five nucleotides BCR-ABL1 insertion mutation of controversial significance confers resistance to imatinib in a patient with chronic myeloid leukemia (CML). Experimental and Molecular Pathology, 2015, 99, 16-18.	0.9	9
35	Flow cytometry for detection of central nervous system disease in acute myeloid leukemia. Leukemia and Lymphoma, 2015, 56, 2190-2192.	0.6	5
36	Calreticulin mutations are not present in patients with myeloproliferative chronic myelomonocytic leukemia. Annals of Hematology, 2015, 94, 869-871.	0.8	1

#	Article	IF	CITATIONS
37	The commitment and evaluation of the quality management plan by professionals from accredited stem cell transplant centers in Spain. Bone Marrow Transplantation, 2014, 49, 990-992.	1.3	1
38	Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with riskâ€adapted protocols. Cancer, 2014, 120, 3958-3964.	2.0	24
39	Correlation of CD11b and CD56 expression in adult acute myeloid leukemia with cytogenetic risk groups and prognosis. Annals of Hematology, 2014, 93, 1483-1489.	0.8	22
40	Treatment of High-Risk Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial. Journal of Clinical Oncology, 2014, 32, 1595-1604.	0.8	227
41	Mobilization and engraftment of peripheral blood stem cells in healthy related donors >55 years old. Cytotherapy, 2014, 16, 406-411.	0.3	13
42	Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors. Medicina ClÃnica, 2013, 141, 95-99.	0.3	10
43	Chronic myelomonocytic leukemia diagnosed by means of mutational analysis in a patient with persistent monocytosis and tuberculosis. Leukemia and Lymphoma, 2013, 54, 2297-2298.	0.6	1
44	Neoplasms and infections as the main causes of death in patients in complete response to HIVâ€related nonâ€Hodgkin lymphoma in the combination antiretroviral therapy era: a study out of a series of 146 patients. British Journal of Haematology, 2013, 162, 289-291.	1.2	1
45	Lack of impact of human immunodeficiency virus infection on the outcome of lymphoma patients transferred to the intensive care unit. Leukemia and Lymphoma, 2012, 53, 1966-1970.	0.6	8
46	Predictive factors for poor peripheral blood stem cell mobilization and peak CD34+cell count to guide pre-emptive or immediate rescue mobilization Cytotherapy, 2012, 14, 823-829.	0.3	50
47	Longâ€term followâ€up of patients with <scp>HIV</scp> â€related diffuse large <scp>B</scp> â€cell lymphomas treated in a phase <scp>II</scp> study with rituximab and <scp>CHOP</scp> . British Journal of Haematology, 2012, 157, 637-639.	1.2	12
48	Post traumatic splenic function depending on severity of injury and management. Translational Research, 2011, 158, 118-128.	2.2	7
49	Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in nonâ∈Hodgkinâ∈™s lymphoma patients at high risk of central nervous system disease in the rituximab era. European Journal of Haematology, 2010, 85, 321-328.	1.1	49
50	Immunohistochemical expression profile and prognosis in patients with diffuse large B-cell lymphoma with or without human immunodeficiency virus infection. Leukemia and Lymphoma, 2010, 51, 2063-2069.	0.6	16
51	Translocation (3;8)(q27;q24) in two cases of triple hit lymphoma. Cancer Genetics and Cytogenetics, 2010, 203, 328-332.	1.0	21
52	Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica, 2010, 95, 589-596.	1.7	240
53	Comparison of the Results of the Treatment of Adolescents and Young Adults With Standard-Risk Acute Lymphoblastic Leukemia With the Programa Español de Tratamiento en HematologÃa Pediatric-Based Protocol ALL-96. Journal of Clinical Oncology, 2008, 26, 1843-1849.	0.8	239
54	Decrease in the frequency of meningeal involvement in AIDS-related systemic lymphoma in patients receiving HAART. Haematologica, 2008, 93, 149-150.	1.7	26

#	Article	IF	CITATIONS
55	El análisis modal de fallos y efectos (AMFE) ayuda a aumentar la seguridad en radioterapia. Revista De Calidad Asistencial: órgano De La Sociedad Española De Calidad Asistencial, 2007, 22, 299-309.	0.6	12
56	Response to highly active antiretroviral therapy as the only therapy in an HIV-infected patient with interfollicular Hodgkin's lymphoma. Leukemia and Lymphoma, 2007, 48, 2058-2059.	0.6	5
57	Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: Two cases with a different outcome. American Journal of Hematology, 2007, 82, 849-851.	2.0	33
58	Outcome and Prognostic Factors in Patients with Hematologic Malignancies Admitted to the Intensive Care Unit: A Single-Center Experience. International Journal of Hematology, 2007, 85, 195-202.	0.7	59
59	Advanced Stage Is the Most Important Prognostic Factor for Survival in Patients with Systemic Acquired Immunodeficiency Syndrome-Related Non-Hodgkin's Lymphoma Treated with CHOP and Highly Active Antiretroviral Therapy. International Journal of Hematology, 2007, 86, 337-342.	0.7	8
60	Systemic thrombotic thrombocytopenic purpura (TTP) following unrelated cord blood transplantation. Leukemia and Lymphoma, 2006, 47, 1173-1175.	0.6	1
61	Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. European Journal of Haematology, 2006, 78, 061114074547002-???.	1.1	63
62	Central nervous system recurrence in adult patients with acute lymphoblastic leukemia. Cancer, 2006, 106, 2540-2546.	2.0	60
63	Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: study of 200 patients. Leukemia and Lymphoma, 2005, 46, 1471-1476.	0.6	20
64	Oral solid form of primary effusion lymphoma mimicking plasmablastic lymphoma. Human Pathology, 2004, 35, 632-635.	1.1	33
65	Hepatosplenic T-Gammadelta Lymphoma in a Patient with Crohn's Disease Treated with Azathioprine. Leukemia and Lymphoma, 2003, 44, 531-533.	0.6	78
66	Improved Outcome of AIDS-Related Lymphoma in Patients With Virologic Response to Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 32, 347-348.	0.9	17
67	Post-transplant Burkitt's Leukemia or Lymphoma. Study of Five Cases Treated with Specific Intensive Therapy (PETHEMA ALL-3/97 Trial). Leukemia and Lymphoma, 2003, 44, 1541-1543.	0.6	6
68	AA-type Amyloid Tumor as an Unsuspected Cause of Residual Mass in a Patient With Large B-cell Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 2002, 43, 681-682.	0.6	10
69	Bone Marrow Changes in Anorexia Nervosa Are Correlated With the Amount of Weight Loss and Not With Other Clinical Findings. American Journal of Clinical Pathology, 2002, 118, 582-588.	0.4	185
70	Favorable Impact of Virological Response to Highly Active Antiretroviral Therapy on Survival in Patients with AIDS-related Lymphoma. Leukemia and Lymphoma, 2002, 43, 1837-1842.	0.6	19
71	Effectiveness of Local Radiotherapy in Primary Extranodal Marginal Zone B-cell Lymphoma of MALT or MALT Lymphoma of Conjunctiva: Study of Four Cases. Leukemia and Lymphoma, 2002, 43, 1975-1977.	0.6	7
72	Successful response to rituximab in a patient with pure red cell aplasia complicating chronic lymphocytic leukaemia. British Journal of Haematology, 2002, 118, 1192-1192.	1.2	19

#	Article	IF	CITATIONS
73	Prognostic impact of highly active antiretroviral therapy in HIV-related Hodgkin's disease. Aids, 2002, 16, 1973-1976.	1.0	32
74	Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. British Journal of Haematology, 2001, 112, 909-915.	1.2	86
75	Usefulness and Reproducibility of Cytomorphologic Evaluations to Differentiate Myeloma From Monoclonal Gammopathies of Unknown Significance. American Journal of Clinical Pathology, 2001, 115, 127-135.	0.4	14
76	Immune hemolytic anemia induced by 6-mercaptopurine. Transfusion, 2000, 40, 75-76.	0.8	12
77	Increased serum levels of CD44s and CD44v6 in patients with AIDS-related non-Hodgkin's lymphoma. Aids, 2000, 14, 1460-1461.	1.0	4
78	Acute promyelocytic leukemia in a patient with idiopathic myelofibrosis. Leukemia, 1999, 13, 492-494.	3.3	12
79	Acute myeloblastic leukemia with minimal myeloid differentiation: phenotypical and ultrastructural characteristics. Leukemia, 1998, 12, 1071-1075.	3.3	25
80	Essential monoclonal gammopathy with an IgM paraprotein that is a cryoglobulin with cold agglutinin and EDTA-dependent platelet antibody properties. British Journal of Haematology, 1998, 100, 603-604.	1.2	12
81	H-RAS 1 Minisatellite Rare Alleles: A Genetic Susceptibility and Prognostic Factor for Non-Hodgkin's Lymphoma. Journal of the National Cancer Institute, 1998, 90, 1095-1098.	3.0	12
82	Low-Grade, Malt-type, Primary B-Cell Lymphoma of the Conjunctiva. Leukemia and Lymphoma, 1997, 28, 203-207.	0.6	12
83	Acute Promyelocytic Leukemia in a HIV Seropositive Patient. Leukemia and Lymphoma, 1997, 26, 621-624.	0.6	25
84	Immunophenotypic and ultrastructural study in peripheral blood neutrophil granulocytes following bone marrow transplantation. British Journal of Haematology, 1997, 98, 299-307.	1.2	2
85	Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. Catalan Group for Bone Marrow Transplantation Journal of Clinical Oncology, 1996, 14, 1353-1363.	0.8	31
86	Phenotypic analysis of blood neutrophils in a patient with chronic idiopathic neutropenia and favorable response to G-CSF treatment. American Journal of Hematology, 1996, 51, 96-97.	2.0	1
87	Incidence and Characteristics of Lymphoid Malignancies in Untreated Myelodysplastic Syndromes. Leukemia and Lymphoma, 1996, 23, 609-612.	0.6	37
88	Probability of the Development of Non-Hodgkin's Lymphoma in Primary Sjögren's Syndrome. Scandinavian Journal of Rheumatology, 1996, 25, 396-397.	0.6	13
89	Erythema nodosum as a presenting feature of T-cell-rich B-cell lymphoma. Annals of Hematology, 1995, 70, 107-108.	0.8	6
90	Systemic Lupus Erythematosus Following Interferon Therapy. Rheumatology, 1994, 33, 787-789.	0.9	33

#	Article	IF	Citations
91	Granular lymphocyte proliferative disorders: A multicenter study of 20 cases. Annals of Hematology, 1994, 68, 285-292.	0.8	6
92	Saccharomyces cervisiae septicemia in septicemia in a patient with myelodsplastic syndrome. American Journal of Hematology, 1993, 43, 325-326.	2.0	43
93	Stereological Study of Human Bone Marrow Adipocytes. Pathology Research and Practice, 1993, 189, 1215-1220.	1.0	8
94	Increased serum tumour necrosis factor during transient remission in acute leukaemia. Lancet, The, 1993, 341, 1600.	6.3	30
95	Electron Microscopic Identification of Parvovirus Virions in Erythroid and Granulocytic-Line Cells in a Patient with Human Parvovirus B19 Induced Pancytopenia. Leukemia and Lymphoma, 1993, 10, 483-487.	0.6	16
96	T-Cell Lymphoblastic Lymphoma with Blood Eosinophilia and Associated Myeloid Malignancy. American Journal of Surgical Pathology, 1993, 17, 92-93.	2.1	2
97	Comparative Study of Spleen Pathology in Drug Abusers With Thrombocytopenia Related to Human Immunodeficiency Virus Infection and in Patients With Idiopathic Thrombocytopenic Purpura: <i>A Morphometric, Immunohistochemical, and Ultrastructural Study</i> . American Journal of Clinical Pathology, 1993, 100, 633-642.	0.4	9
98	B-Type Large-Cell Primary Splenic Lymphoma with Massive Involvement of the Red Pulp. Acta Haematologica, 1993, 89, 46-49.	0.7	18
99	Neutrophilic Pustulosis Associated with Chronic Myeloid Leukemia: A Special Form of Sweet's Syndrome. Acta Haematologica, 1992, 88, 154-157.	0.7	27
100	A SECOND BONE MARROW BIOPSY AS A CAUSE OF A FALSE DIAGNOSIS OF MYELOFIBROSIS. British Journal of Haematology, 1992, 80, 407-409.	1.2	5
101	The value of detecting surface and cytoplasmic antigens in acute myeloid leukaemia. British Journal of Haematology, 1992, 81, 178-183.	1.2	33
102	Intracytoplasmic immunoglobulin inclusions in a case of chronic lymphocytic leukemia. American Journal of Hematology, 1992, 40, 316-317.	2.0	1
103	Dyserythropoiesis in iron-deficiency anemia: Ultrastructural reassessment. American Journal of Hematology, 1992, 41, 147-150.	2.0	8
104	Liver Dysfunction following Splenectomy in Idiopathic Myelofibrosis: A Study of 10 Patients. Acta Haematologica, 1991, 85, 184-188.	0.7	50
105	Acquired Amegakaryocytic Thrombocytopenic Purpura Associated with Immunoglobulin Deficiency. Acta Haematologica, 1991, 85, 34-36.	0.7	6
106	Interferon alpha-2b for Essential Thrombocythaemia: Results in 13 Previously Untreated Patients. Leukemia and Lymphoma, 1991, 4, 351-354.	0.6	3
107	ULTRASTRUCTURAL STUDY OF ERYTHROCYTES CONTAINING PAPPENHEIMER BODIES IN A CASE OF CONGENITAL SIDEROBLASTIC ANAEMIA (CSA). British Journal of Haematology, 1991, 78, 577-578.	1.2	11
108	Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer, 1991, 67, 2658-2663.	2.0	244

#	Article	IF	CITATIONS
109	Clinical significance of the presence of myeloid associated antigens in acute lymphoblastic leukaemia. British Journal of Haematology, 1990, 75, 202-207.	1.2	66
110	Usefulness of Y-body study on bone marrow smears to demonstrate the origin of fibroblast stromal cells in allogeneic bone marrow transplantation. Blut, 1990, 61, 14-16.	1.2	2
111	Cyclooxygenase products of metabolism of arachidonic acid in mouse macrophages exposed to N-phenyllinoleamide from toxic oil samples. Prostaglandins Leukotrienes and Essential Fatty Acids, 1990, 39, 147-149.	1.0	16
112	Variations of fat tissue fraction in abnormal human bone marrow depend both on size and number of adipocytes: a stereologic study. Blood, 1990, 76, 892-895.	0.6	2
113	Prognostic Evaluation of Initial Bone Marrow Histopathological Features in Chronic Granulocytic Leukemia. Acta Haematologica, 1989, 82, 12-15.	0.7	13
114	Adult T-cell Leukemia in a Chilean Resident in Spain: Long-Lasting Remission after 2-Deoxycoformycin Treatment. Leukemia and Lymphoma, 1989, 1, 47-49.	0.6	9
115	Morphologic and morphometric light and electron microscopic studies of the spleen in patients with hereditary spherocytosis and autoimmune haemolytic anaemia. British Journal of Haematology, 1989, 72, 246-253.	1.2	16
116	Iron stores in essential thrombocythaemia. Blut, 1989, 58, 291-294.	1.2	6
117	Is the histological classification of chronic granulocytic leukaemia justified from the clinical point of view?. European Journal of Haematology, 1989, 42, 150-154.	1.1	16
118	Bone marrow lymphoid nodules in myeloproliferative disorders: association with the nonmyelosclerotic phases of idiopathic myelofibrosis and immunological significance. British Journal of Haematology, 1988, 70, 279-282.	1.2	25
119	Chronic neutrophilic leukemia with marked myelodysplasia terminating in blast crisis. Blut, 1988, 56, 75-78.	1.2	16
120	Large B-cell lymphoma presenting with lytic bone lesions and hypercalcaemia. Histopathology, 1988, 13, 477-478.	1.6	1
121	Cutaneous Myeloid Metaplasia with Dysplastic Features in Idiopathic Myelofibrosis. International Journal of Dermatology, 1988, 27, 179-180.	0.5	9
122	Intestinal Lymphoma in a Patient with Chronic Lymphocytic Leukemia of Atypical Phenotype: Richter's Syndrome of Unusual Presentation. Acta Haematologica, 1988, 80, 116-119.	0.7	6
123	Treatment of alkylating resistant multiple myeloma with vincristine, BCNU, doxorubicin and prednisone (VBAP). European Journal of Cancer & Clinical Oncology, 1986, 22, 1193-1197.	0.9	10
124	Cross-resistance to alkylating agents in multiple myeloma. Cancer, 1983, 52, 786-789.	2.0	15
125	XENOGENEIC HYBRIDOMA CELLS CONTAIN AND SECRETE VIRUS PARTICLES. Lancet, The, 1983, 322, 1255.	6.3	0
126	ULTRASTRUCTURAL MARKERS IN AIDS. Lancet, The, 1983, 322, 284-285.	6.3	51

#	Article	IF	CITATIONS
127	CYTOPLASMIC INCLUSIONS IN LYMPHOCYTES OF CHRONIC LYMPHOCYTIC LEUKAEMIA. Scandinavian Journal of Haematology, 1983, 31, 510-511.	0.0	5
128	Prognosis of chronic lymphocytic leukemia: a multivariate survival analysis of 150 cases. Blood, 1982, 59, 1001-1005.	0.6	85
129	Transient dyserythropoiesis in repopulated human bone marrow following transplantation: an ultrastructural study. British Journal of Haematology, 1982, 50, 63-73.	1.2	13
130	IDIOPATHIC MYELOFIBROSIS: A POSSIBLE ROLE OF IMMUNOLOGICAL PHENOMENA. British Journal of Haematology, 1982, 50, 375-380.	1.2	6
131	Specific cutaneous manifestations of Waldenstrom's macroglobulinaemia. A report of two cases*. British Journal of Dermatology, 1982, 106, 217-222.	1.4	61
132	Ultrastructure of supravitally stained red cells in haemoglobin H disease. International Journal of Laboratory Hematology, 1982, 4, 89-90.	0.2	0
133	Severe-glucose-6-phosphate dehydrogenase (G6PD) deficiency associated with chronic hemolytic anemia, granulocyte dysfunction, and increased susceptibility to infections: description of a new molecular variant (G6PD Barcelona). Blood, 1982, 59, 428-434.	0.6	6
134	Comparative morphology of granulocytes collected by three methods of leukapheresis. A light microscopy and transmission electron microscopy study. Transfusion, 1981, 21, 517-526.	0.8	7
135	Congenital dyserythropoietic anemia type I. Blut, 1981, 42, 47-52.	1.2	4
136	Prognosis in Acquired Aplastic Anaemia A Multivariate Statistical Analysis of 80 Cases. Scandinavian Journal of Haematology, 1981, 26, 321-329.	0.0	10
137	Thrombocytosis in Quiescent Chronic Granulocytic Leukaemia after Vincristine and 6-Mercaptopurine Therapy. Acta Haematologica, 1980, 64, 224-226.	0.7	4
138	Ultrastructural Findings in Acute and Chronic Graft-Vs-Host Reaction of the Skin*. Journal of Cutaneous Pathology, 1980, 7, 354-363.	0.7	11
139	Acute and chronic graft-vs-host reaction in skin: report of two cases*. British Journal of Dermatology, 1980, 102, 461-466.	1.4	8
140	Low-dose vincristine in the treatment of corticosteroid-refractory idiopathic thrombocytopenic purpura (ITP) in non-splenectomized patients. Postgraduate Medical Journal, 1980, 56, 711-714.	0.9	18
141	Lymphocyte Size and Survival of Patients with Chronic Lymphocytic Leukaemia (Bâ€₹ype). Scandinavian Journal of Haematology, 1980, 24, 315-320.	0.0	7
142	Triosephosphate isomerase deficiency with hemolytic anemia and severe neuromuscular disease. Familial and biochemical studies of a case found in Spain. Human Genetics, 1978, 42, 171-180.	1.8	38
143	Blood polymorphonuclear dysfunction in patients with alcoholic cirrhosis. European Journal of Clinical Investigation, 1977, 7, 571-577.	1.7	69
144	Metabolic activity of phagocytosing granulocytes in chronic granulocytic leukemia: ultrastructural observation of a degranulation defect. Blood, 1977, 50, 93-106.	0.6	3